Please ensure Javascript is enabled for purposes of website accessibility
neurolutions logo

Talk to Our Team

Find out if IpsiHand™ is a good fit for your patients.

Your chronic stroke patients could benefit from a prescription to IpsiHand. Introduce this groundbreaking rehabilitation system into their therapy routines.

The Science of IpsiHand

IpsiHand therapy has been shown to improve function in the upper extremity after a stroke in three separate clinical trials. This evidence-based treatment for stroke UE rehabilitation esteems stroke survivors with dignity and autonomy, and the equipment has been designed to be accessible and able to put one using just one hand.

The EEG headset pulls cortical signals from hand regions in the primary cortex of the ipsilateral cerebral hemisphere (the healthy, non-lesioned side of the brain).

The IpsiHand is FDA-cleared and certified as a medical device with both ISO 13485 and MDSAP. It’s able to be prescribed to your patients and billed through an approved CMS code. The FDA has also designated IpsiHand as a breakthrough technology for chronic stroke rehabilitation.

Clinical studies have proven IpsiHand as a therapeutic device that can make meaningful improvements, measured through Fugl-Meyer Upper Extremity (UEFM) assessment and Action Research Arm Test (ARAT) to see who met Minimal Clinically Important Difference.

+10.2 AMAT
IpsiHand has been shown to increase independence in daily living activities, an average +10.2 on the AMAT (Arm Motor Ability Test).
+7.7 FUGL-Meyer
Patients fitting acceptance criteria average +7.7 points on the Fugl-Meyer, the gold standard test for arm function after stroke.